CapsulateBio
CapsulateBio develops robotic oral drug delivery systems that transform injectable biologics into swallowable pills. The Capsulate SI™ and ST™ platforms mechanically deliver liquid or solid drug material directly into gastrointestinal tissue, achieving injectable-like bioavailability for therapeutics over 1,000× larger than conventional oral delivery systems can handle.
- Healthcare Technology
- Robotics
- Medical Devices
- Biotechnology
- Hardware
Funding
Founders
Founder details are not available yet.
Product
Problem
Biologic medicines—including peptides, monoclonal antibodies, and nucleic acids—are among the most powerful therapeutics available, but they typically require injection, creating a significant burden for patients and limiting adherence. Conventional oral delivery technologies rely on chemical absorption enhancers that deliver less than 5% bioavailability, making them unsuitable for most biologics and leaving a critical gap in patient-friendly drug administration.
Solution
CapsulateBio provides robotic oral drug delivery systems that transform injectable biologics into oral medicines. The Capsulate SI™ platform features an easy-to-swallow capsule that safely passes through the stomach and delivers liquid drug material directly into the small intestinal wall, achieving injectable-like bioavailability. The Capsulate ST™ platform delivers solid drug material into the stomach wall using a capsule the size of a small blueberry. Both platforms carry biologic drug material safely through the gastrointestinal tract and pass naturally through the body after delivery. Unlike conventional oral technologies limited to small molecules and peptides, CapsulateBio's platforms can deliver all therapeutic modalities, including materials over 1,000× larger than conventional oral therapies. The company's approach aims to improve patient adherence, reduce pharmacokinetic variability, and expand the therapeutic potential of biologics.
Target Audience
Primary customers include pharmaceutical and biotechnology companies developing biologic therapeutics who need oral delivery options, as well as patients and physicians seeking alternatives to injectable biologics.
Features
- Robotic capsules that mechanically deliver drug material directly into gastrointestinal tissue, bypassing the absorption barrier that limits conventional oral biologics
- Injectable-like bioavailability comparable to subcutaneous injection, enabling therapeutically relevant dosing for biologics
- Two platform designs: Capsulate SI™ for liquid drug delivery into the small intestine and Capsulate ST™ for solid drug delivery into the stomach wall
- Small, patient-friendly capsule formats comparable to common medicine capsules and a small blueberry in size
- Validated mRNA delivery using branched hybrid poly(β-amino ester) nanoparticles combined with milli-injector capsules, demonstrating protein translation in gastric tissue and systemic uptake in rodent and pig models
- Engineered to deliver biologics over 1,000× larger than conventional oral delivery systems